Rational design of a potent macrocyclic peptide inhibitor targeting the PD-1/PD-L1 protein-protein interaction.
Quick Facts
What This Study Found
JMPDP-027 cyclic peptide blocked PD-1/PD-L1 with EC50 of 5.9 nM (comparable to pembrolizumab) and showed potent in vivo anticancer activity.
Key Numbers
EC50 5.9 nM; comparable to pembrolizumab; serum stable; no toxicity; in vivo efficacy ≈ anti-PD-L1 mAb
How They Did This
Rational design and optimization of macrocyclic peptide. T cell restoration assay, serum stability, cytotoxicity, and CT26 colon carcinoma mouse model.
Why This Research Matters
Antibody checkpoint inhibitors revolutionized cancer treatment but are expensive. Peptide alternatives could make immunotherapy more accessible.
What This Study Doesn't Tell Us
Single mouse tumor model. Manufacturing scalability not demonstrated. Long-term pharmacokinetics and safety unknown. Head-to-head with pembrolizumab not done in vivo.
Trust & Context
- Original Title:
- Rational design of a potent macrocyclic peptide inhibitor targeting the PD-1/PD-L1 protein-protein interaction.
- Published In:
- RSC advances, 11(38), 23270-23279 (2021)
- Authors:
- Miao, Qi, Zhang, Wanheng, Zhang, Kuojun, Li, He, Zhu, Jidong, Jiang, Sheng
- Database ID:
- RPEP-05608
Evidence Hierarchy
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05608APA
Miao, Qi; Zhang, Wanheng; Zhang, Kuojun; Li, He; Zhu, Jidong; Jiang, Sheng. (2021). Rational design of a potent macrocyclic peptide inhibitor targeting the PD-1/PD-L1 protein-protein interaction.. RSC advances, 11(38), 23270-23279. https://doi.org/10.1039/d1ra03118j
MLA
Miao, Qi, et al. "Rational design of a potent macrocyclic peptide inhibitor targeting the PD-1/PD-L1 protein-protein interaction.." RSC advances, 2021. https://doi.org/10.1039/d1ra03118j
RethinkPeptides
RethinkPeptides Research Database. "Rational design of a potent macrocyclic peptide inhibitor ta..." RPEP-05608. Retrieved from https://rethinkpeptides.com/research/miao-2021-rational-design-of-a
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.